Totos G, Gizaris V, Papaevangelou G
Department of Microbiology and Immunology, Naval and Veterans Hospital, Athens, Greece.
Vaccine. 1997 Aug;15(11):1252-3. doi: 10.1016/s0264-410x(97)00022-4.
The recent development of safe and effective inactivated hepatitis A vaccines provides the opportunity to control hepatitis A. However, effective control will depend upon the duration of protection provided by the vaccine. Evaluation of persistence of antibodies over time is essential for the determination of vaccination schedules and strategies. For this purpose blood samples were obtained from 140 volunteers, 5 years after the administration of three 720 ELISA units (EU) doses of an inactivated hepatitis A vaccine according to a 0, 1 and 6 month schedule. All serum samples were tested for anti-hepatitis A virus (HAV) antibodies using a sensitive ELISA inhibition assay. All subjects, except one, had anti-HAV titres > or = 20 mIU ml-1. The geometric mean titre (GMT) was 1258 mIU ml-1. All individual titres were at least 10 times higher than the minimum protective level. According to the rate of antibody level decrease over time, the predicted duration of antibodies is estimated to be at least 20 years.
安全有效的甲型肝炎灭活疫苗的最新研发为控制甲型肝炎提供了契机。然而,有效控制将取决于疫苗所提供的保护时长。随着时间推移评估抗体的持久性对于确定疫苗接种计划和策略至关重要。为此,在按照0、1和6个月的接种程序接种三剂720酶联免疫吸附测定单位(EU)的甲型肝炎灭活疫苗5年后,从140名志愿者身上采集了血样。使用灵敏的酶联免疫吸附抑制试验对所有血清样本进行了抗甲型肝炎病毒(HAV)抗体检测。除一人外,所有受试者的抗-HAV滴度均≥20 mIU/ml。几何平均滴度(GMT)为1258 mIU/ml。所有个体滴度至少比最低保护水平高10倍。根据抗体水平随时间下降的速率,预计抗体持续时间至少为20年。